Disease Control Data, nr-axSpA

Review separate clinical trial data relating to the efficacy of RINVOQ® in non-radiographic axial spondyloarthritis patients. See Important Safety Info, including BOXED WARNING, and full Prescribing Info.

FDA Approval Of The First nr-AxSpA Biologics Projecting Regulatory Market Dynamics

Study flow diagram. axSpA: axial spondyloarthritis; TNF-α: tumor

Understanding Axial Spondyloarthritis: A Primer for Managed Care

A Road Map of the Axial Spondyloarthritis Continuum - ScienceDirect

Disease Control Data, nr-axSpA

Axial Spondyloarthritis

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial

AB1006 PULMONARY MANIFESTATIONS OF AXIAL SPONDYLOARTHRITIS (AXSPA): A SYSTEMATIC LITERATURE REVIEW

Looking through the window of opportunity in axial spondyloarthritis? - ScienceDirect

Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis, Arthritis Research & Therapy

Axial Spondyloarthritis RINVOQ® (upadacitinib)

Axial Spondyloarthritis Disease Education Resources - Lilly Medical Education

Frontiers Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum

Extra-articular manifestations and burden of disease in patients with radiographic and non-radiographic axial spondyloarthritis.

Metabolite levels in the AS group, nr-axSpA group and asymptomatic